| Bioactivity | ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection[1][2]. |
| Target | cccDNA. |
| Invitro | ccc_R08 (0.3, 1.0, 3.2, 10, 32 µM; 5 days) significantly reduces the level of cccDNA, protein-free RC-DNA, and double stranded linear DNA (DL-DNA) in HepDES19 cells[1].ccc_R08 (0-100 µM) dose-dependently reduces the level of extracellular HBeAg from HepDES19 cells, with IC50 of ~0.1 µM[1]. Western Blot Analysis[1] Cell Line: |
| In Vivo | ccc_R08 (20 mg/kg; p.o.; twice per day for 2 weeks) clears cccDNA from the liver of HBVcircle mice[1].ccc_R08 (10, 15, 20, 30 mg/kg; p.o.; twice per day for 2 weeks) significantly decreases the serum level of pgRNA in a dose-dependent manner, and the reduction in pgRNA is quantitatively correlated with that in liver cccDNA at different doses[1]. Animal Model: |
| Name | ccc_R08 |
| Formula | C22H19ClO6 |
| Molar Mass | 414.84 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Wang L, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. [2]. Ligat G, et al. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatol Rep. 2020 Sep;19(3):235-244. |